Endometrial cancer risk with medroxyprogesterone appears to decrease with a greater number of days used per month

By  

Reactions Weekly, Vol. 1, Iss. 1027, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Risedronate

By Goa K.L.   Balfour J.A.  

Drugs & Aging, Vol. 13, Iss. 1, 1998-07 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite

Is two days of intermittent energy restriction per week a feasible weight loss approach in obese males? A randomised pilot study

By  

NUTRITION AND DIETETICS, Vol. 75, Iss. 1, 2018-02 ,pp. : 65-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

By Lê Lyly H.   Erlichman Charles   Pillon Linda   Thiessen Jake J.   Day Andrew   Wainman Nancy   Eisenhauer Elizabeth A.   Moore Malcolm J.  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 159-167

Springer Publishing Company

Access to resources Recommend Favorite

Risedronate: A Viewpoint by Sanjeev Patel

By Patel S.  

Drugs & Aging, Vol. 13, Iss. 1, 1998-07 ,pp. : 92-92

Adis International

Access to resources Recommend Favorite